bevacizumab-vikg

ISELIN, N.J., August 14, 2026 Outlook Therapeutics, Inc. is advancing preparations for the U.S. commercial launch of LYTENAVA™ (bevacizumab-vikg)...

ISELIN, N.J., July 24, 2026 Outlook Therapeutics has achieved a major regulatory milestone after the U.S. Food and Drug...